biotech · Chronic Hepatitis D Virus (HDV) Infection · Chronic Hepatitis B · VIR
Vir Biotechnology
Vir Biotechnology patent portfolio — 6 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 1800 Owens St, Suite 900, San Francisco, California 94158, US
- Founded
- 2016
- Employees
- 479
- Programs
- 34
- Drugs
- 17
- Patents
- 6
Vir Biotechnology patents
6 pharmaceutical patents indexed for Vir Biotechnology. 0 expire within 24 months.
Vir Biotechnology has 6 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12404318
Combination HBV therapy
granted -
US 11628215
HIV vaccines comprising one or more population episensus antigens
granted -
US 11554168
HIV vaccines comprising one or more population episensus antigens
granted -
US 11479599
Antibodies against SARS-CoV-2 and methods of using the same
granted -
US 11168128
Antibodies against SARS-CoV-2 and methods of using the same
granted -
US 10894078
HIV vaccines comprising one or more population episensus antigens
granted
Frequently asked questions
How many patents does Vir Biotechnology have?
6 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Vir Biotechnology patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.